Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma
Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma
复制标题
DOI：
10.1080/00016480600702100
复制
发表时间：
2006-10-01
影响因子：
1.4
通讯作者：
Nishiyama, Yukihiro
中科院分区：
文献类型：
--
作者：
Fujimoto, Yasushi;Mizuno, Terukazu;Nishiyama, Yukihiro
我们开发了一种新型的具有复制能力的溶瘤单纯疱疹病毒(HSV)，命名为HF10，并在各种动物模型中评估了其抗癌效果。我们报道了一项头颈部鳞状细胞癌(HNSCC)患者皮下结节内注射HF10的初步研究。HF10能有效感染人HNSCC细胞，引起肿瘤细胞广泛死亡，无明显不良反应，是治疗HNSCC的一种有前景的药物。为了评估HF10对人HNSCC的治疗潜力，我们对两名复发转移性HNSCC患者进行了毒性和疗效的初步研究。对于每个患者，转移的皮肤结节注射HF10，每天一次，连续3天。他们监测全身不良反应，并在注射后第13天(患者1)或第15天(患者2)切除注射的结节进行组织化学检查。HF10在肿瘤结节中复制、扩散良好，并在相当数量的肿瘤细胞中导致细胞死亡，没有任何明显的不良反应。
We have developed a novel replication-competent, oncolytic herpes simplex virus (HSV), named HF10, and have evaluated its anticancer efficacy in a variety of animal models. We report a pilot study of intratumoral injection of HF10 into subcutaneous nodules in patients with head and neck squamous cell carcinoma (HNSCC). HF10 efficiently infected human HNSCC cells and caused extensive tumor cell death without any significant adverse effects, suggesting that HF10 represents a promising therapy for HNSCC in humans. To assess the therapeutic potential of HF10 in human HNSCC, we performed a preliminary study of toxicity and efficacy in two patients with recurrent metastatic HNSCC. For each patient, a metastatic skin nodule was injected with HF10 once a day for 3 days. They were monitored for systemic adverse effects, and the injected nodules were excised at day 13 ( patient 1) or day 15 ( patient 2) after injection for histochemical examination. HF10 replicated, spread well in the tumor nodules, and caused cell death in a considerable population of tumor cells without any significant adverse effects.